Want to see CH:YPSN full AI Analyst Report?
YPSN Stock Chart & Stats
CHF382.40
CHF9.40(2.46%)
At close: 4:00 PM EDT
CHF382.40
CHF9.40(2.46%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF441.50
Previous CloseN/A
Volume9.81K
Average Volume (3M)17.31K
Market Cap
CHF5.21B
Enterprise ValueCHF4.81B
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)23.4
Beta0.65
Next Earnings
Nov 11, 2026EPS Estimate
5.25Next Dividend Ex-DateN/A
Dividend Yield1.13%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,649,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF342.00Price Target Upside-10.56% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)13.19
Revenue Forecast (FY)CHF710.32M
Bulls Say, Bears Say
Bulls Say
Profitability & Operating Cash FlowYpsomed's >CHF300m operating cash flow and material net income improvement show durable earnings power and internal funding capacity. Strong OCF supports reinvestment, debt reduction and targeted buybacks, enhancing financial flexibility while longer capex programs run.
Delivery Systems Growth & PipelineCore Delivery Systems (80%+ of group) delivered sustained commercial traction: high single‑digit to double‑digit growth, record deal flow and a deep pipeline with ~70% hit rate. This mix and client breadth create durable revenue visibility as development wins convert to recurring manufacturing volumes.
Platform Innovation & Time‑to‑ClinicNew recyclable platforms extend IP life and differentiate Ypsomed on sustainability and design, strengthening customer stickiness. Coupled with Clear‑to‑Clinic cut from 18 to 6 months, these structural capabilities speed customer commercialization and raise long‑term competitive barriers.
Bears Say
Persistent Negative Free Cash FlowDespite high operating cash flow, multi‑year negative free cash flow indicates heavy capex and working‑capital absorption. Persistent FCF deficits constrain liquidity and strategic optionality, increasing reliance on financing or equity and raising sensitivity to any decline in operating performance.
Recent Revenue ContractionA group revenue decline in 2026 highlights top‑line volatility tied to project timing and structural changes (e.g., phased‑out contract manufacturing). This weakens near‑term growth visibility and increases pressure to convert the expansive pipeline into stable production revenues over the medium term.
Ramp‑up & Footprint Execution RiskLarge multi‑site capacity investments (tool shops, factory expansions) create multi‑year ramp‑up and stranded‑cost risk. Execution delays or lower-than-expected absorption can depress margins, cash flow and ROCE temporarily, making near‑term profitability more sensitive to project delivery.
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF441.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF5.21B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 11, 2026 which is in 106 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Overvalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF4.4 which represents an annual dividend yield of 1.13%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.25.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,649,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.33%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
YPSN Stock 12 Month Forecast
Average Price Target
CHF342.00
▼(-10.56% Downside)